Pfizer Touts Prevnar 13 Superiority As Initial Vaccine In Older Persons Before ACIP

Pfizer got to present a dry run of its case for Prevnar 13 as a superior initial vaccine for adults 50 and older to the Centers for Disease Control’s Advisory Committee on Immunization Practices Oct. 26.